Filter by:
Revita
TOS, October 2016
Duodenal mucosal hydrothermal ablation: a new procedure designed for metabolic gain
Maggs presented at The Obesity Society (TOS). New Orleans, LA, USA, October 2016
Revita
UEGW, October 2016
Endoscopic Duodenal Mucosal Resurfacing treatment for type 2 diabetes: Early multicenter experience
van Baar, et al. presented poster at United European Gastroenterology Week (UEGW). Vienna, Austria, October 2016
Revita
VideoGIE, 1(1), 10-11, September 2016
Hydrothermal duodenal mucosal resurfacing: a novel procedural therapy for metabolic disease
Galvao, et al.
Revita
Diabetes Care, 39, 1-8, August 2016.
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study
Rajagopalan, et al.
Revita
ADA, June 2016
Endoscopic Duodenal Mucosal Resurfacing (DMR) Improves Metabolic Measures in Type 2 Diabetes: First-in-Human Study 6-Month Data
Cherrington, et al. presented at 76th American Diabetes Association (ADA). New Orleans, Louisiana, USA, June 2016. [Oral]
Revita
DDW, May 2016
Early experience of Duodenal Mucosal Resurfacing treatment for Type 2 Diabetes when expanding from single to multiple sites
van Baar, et al. presented at Digestive Disease Week (DDW). San Diego, Calif, USA, May 2016
Revita
EASL, April 2016.
Endoscopic duodenal mucosal resurfacing (DMR) improves metabolic measures including hepatic transaminase levels in patients with type 2 diabetes (T2D): Data from a first-in-human study
Rajagopalan, et al. presented poster at The International Liver Congress-European Association for the Study of the Liver (EASL). Barcelona, Spain, April 2016.
Revita
GTC Diabetes Summit, April 2016.
Duodenal mucosa: a target for treating metabolic disease
Rajagopalan, et al. presented at 9th Diabetes Drug Discovery & Development Conference-GTC Diabetes Summit. Boston, Massachusetts, USA, April 2016.
Revita
EASL, April 2016.
Endoscopic Duodenal Mucosal Resurfacing (DMR) Improves Metabolic Measures, Including Hepatic Transaminase Levels, in Patients with Type 2 Diabetes: Data from a First-in-Human Study
Rajagopalan, et al. presented at The International Liver Congress-European Association for the Study of the Liver (EASL). Barcelona, Spain, April 2016.